Ankle-Brachial Index Test: What It Reveals About Your Circulation
The ankle-brachial index (ABI) is the simplest, most cost-effective, and most widely validated test for peripheral arterial disease (PAD) — a condition affecting 200 to 250 million people worldwide in which atherosclerotic narrowing of the arteries reduces blood flow to the legs. The test takes 15 to 20 minutes, requires only a blood pressure cuff, a handheld Doppler probe, and basic vascular training, and produces a single number that simultaneously diagnoses PAD, stratifies its severity, and quantifies systemic cardiovascular risk.
PAD is dramatically underdiagnosed despite being as common as coronary artery disease and sharing its mortality risk. Many patients attribute their leg fatigue, cramping, or weakness to aging, arthritis, or deconditioning — never recognizing that these symptoms represent arterial insufficiency that is treatable and that signals markedly elevated risk of heart attack and stroke. The ABI test cuts through this diagnostic gap with a straightforward, accessible measurement. Understanding how the test is performed, what the numbers mean, and what comes next based on results helps patients take meaningful action after receiving their ABI results.
Why the Ankle-Brachial Index Is Measured — The Physiological Rationale
In a healthy arterial system, the systolic blood pressure measured at the ankle should be equal to or slightly higher than the systolic pressure at the arm — because blood flows continuously from the heart through the aorta, iliac arteries, femoral arteries, popliteal arteries, and tibial arteries to the ankle, and in a normal system without obstructions, pressure is transmitted fully. The normal ABI is therefore 1.00 to 1.40 (ankle pressure equal to or slightly higher than brachial pressure, reflecting the pulse wave amplification that normally occurs in the peripheral arteries).
When a significant obstruction (atherosclerotic stenosis or occlusion) is present in the arterial supply to the leg — whether in the aorta, iliac, femoral, or tibial arteries — the pressure downstream from the obstruction drops because energy is lost driving blood through the narrowed segment. This pressure drop is proportional to the severity of the obstruction: mild stenosis causes small pressure drops; severe stenosis or total occlusion causes large, clinically significant pressure drops. The ABI captures this pressure differential directly and quantifies its magnitude — making it a sensitive and specific measure of hemodynamically significant arterial obstruction in the lower extremities.
Who Should Get an ABI Test — Screening Indications
The ACC/AHA Guidelines on the Management of Lower Extremity Peripheral Artery Disease recommend ABI screening for the following groups:
- Adults aged 65 years or older
- Adults aged 50 to 64 with at least one PAD risk factor: smoking history (at least 10 pack-years), diabetes mellitus, hypertension, hyperlipidemia, or family history of PAD
- Any patient with exertional leg symptoms — cramping, aching, tightness, or weakness in the calf, thigh, or buttock that occurs with walking and resolves within 10 minutes of rest (classic claudication pattern)
- Patients with non-healing lower extremity wounds or ulcers
- Patients with an absent or diminished pedal pulse on physical examination
- Patients with known atherosclerotic disease in another territory (coronary artery disease, carotid artery disease, aortic aneurysm) — because PAD coexists in 20 to 40% of patients with CAD and 30 to 50% of patients with carotid artery disease
Importantly, most PAD patients are asymptomatic or have atypical symptoms — only 20 to 30% have classic claudication. Silent PAD identified by ABI screening carries the same cardiovascular mortality risk as symptomatic PAD and warrants the same intensity of cardiovascular risk factor management, making screening of at-risk asymptomatic patients clinically important.
Symptoms of Peripheral Arterial Disease — What Leads to ABI Testing
Understanding the clinical spectrum of PAD symptoms helps patients recognize when their leg symptoms should prompt a discussion with their doctor about ABI testing:
Classic claudication: Reproducible cramping, aching, tightness, or fatigue in a muscle group (most commonly the calf, but also the thigh in femoral disease or the buttock in aortoiliac disease) that consistently occurs after a predictable walking distance or duration and resolves completely within 10 minutes of rest. The key distinguishing feature from musculoskeletal pain: claudication disappears completely with rest (because the demand for blood flow drops when walking stops, and even compromised circulation meets the resting requirement) and recurs at the same walking distance. Musculoskeletal pain from arthritis or spinal stenosis typically does not follow this predictable onset-rest-resolution pattern and may require positional changes (sitting) for relief rather than simple standing rest.
Atypical leg symptoms: Many PAD patients — particularly women, diabetic patients, and elderly patients — describe leg symptoms that do not fit the classic claudication pattern: non-exertional leg pain, leg weakness or fatigue without cramping, walking limitations from multiple causes simultaneously. These atypical presentations are a major reason PAD is underdiagnosed — ABI testing in all patients with any exertional leg limitation would identify significantly more PAD cases than restricting testing to those with classic claudication.
Critical limb-threatening ischemia (CLTI): The most severe manifestation of PAD — rest pain (ischemic pain at rest, typically in the forefoot and toes, often worse at night, relieved by hanging the foot over the bed edge or dependent position), tissue loss (non-healing wounds or ulcers, typically on the foot or toes, that fail to heal because arterial blood supply is insufficient for wound healing), and gangrene (black, necrotic tissue indicating advanced tissue death from ischemia). CLTI requires urgent vascular surgery evaluation — limb loss risk is 25 to 40% per year without revascularization.
After a Positive ABI — What Treatment Looks Like
A diagnosis of PAD by ABI (ABI less than 0.90) initiates a comprehensive management approach targeting both the limb symptoms and the systemic cardiovascular risk:
Supervised exercise therapy: The most evidence-based and cost-effective treatment for claudication. Structured programs — walking 3 sessions per week at 60 to 75% of maximum heart rate, for 30 to 60 minutes per session, for 6 months — improve the pain-free walking distance by 150% on average and maximum walking distance by 200% compared to unsupervised walking. The mechanism involves adaptation of collateral circulation, skeletal muscle metabolism (increased oxidative enzyme capacity, mitochondrial density), and endothelial function. The CLEVER trial directly compared supervised exercise to stenting for aortoiliac PAD and found equivalent or superior walking improvement with exercise at 18 months — supporting exercise as the first-line treatment for claudication before revascularization is considered.
Medical therapy: High-intensity statin therapy (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) reduces LDL and stabilizes atherosclerotic plaque, reducing cardiovascular events and PAD progression — target LDL less than 70 mg/dL in high-risk PAD. Antiplatelet therapy (aspirin 75–100 mg daily or clopidogrel 75 mg daily) reduces cardiovascular events. The COMPASS trial demonstrated that low-dose rivaroxaban (2.5 mg twice daily) plus aspirin 100 mg daily further reduced major adverse cardiovascular events and major adverse limb events (acute limb ischemia, amputation) compared to aspirin alone in patients with PAD and established cardiovascular disease. Blood pressure control (target less than 130/80 mmHg) and diabetes management (HbA1c less than 7.0%) reduce PAD progression. Smoking cessation is the single most impactful intervention — smoking cessation halts PAD progression and reduces amputation risk by 80%.
See our related articles on vascular ultrasound for circulation problems, how doctors diagnose heart disease, common heart tests explained, major risk factors for heart disease, and blood pressure monitoring. The American Heart Association PAD information, NHLBI PAD diagnosis guide, and ACC/AHA PAD management guidelines provide authoritative clinical standards.
- Gerhard-Herman MD, et al. 2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease. J Am Coll Cardiol. 2017;69(11):e71-e126.
- Ankle Brachial Index Collaboration. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality. JAMA. 2008;300(2):197-208.
- Hiatt WR, et al. CLEVER: supervised exercise versus primary stenting for claudication. Circulation. 2015;131(15):1313-1322.
- Eikelboom JW, et al. COMPASS: rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319-1330.
- CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-1339.
How to Perform a Home Blood Pressure Cuff ABI — Patient Self-Monitoring
While the gold-standard ABI is performed by a trained vascular technician in a clinical setting using a continuous-wave Doppler probe, patients with known PAD can monitor disease progression at home using an oscillometric blood pressure monitor with appropriate cuffs at the ankle. Home ABI monitoring is not yet standard of care and has limitations compared to Doppler-based ABI — but it provides a practical means of self-surveillance for patients in areas with limited specialist access or between scheduled clinic visits:
A validated automated oscillometric blood pressure device (such as the OMRON HEM-907 or similar oscillometric monitors validated for ABI measurement) measures oscillations in arterial wall movement during cuff deflation to calculate systolic pressure. The patient lies supine for 10 minutes before measurement. Standard blood pressure cuffs are applied to both arms (brachial measurement) and both ankles (ankle measurement — the cuff is applied just above the medial malleolus, the inner ankle bone). The device inflates and deflates the cuffs sequentially, measuring pressures at each site. Home ABI devices calculate the ABI automatically from these measurements. The advantage of automated devices is elimination of operator skill requirements; the limitation is lower accuracy compared to Doppler ABI for very low ankle pressures (where oscillometric signal is too small to detect accurately) — precisely the range most important in severe PAD. For clinical management decisions, Doppler ABI remains the reference standard.
Patients who monitor their ABI at home should report any ABI decrease of 0.15 or greater from their baseline to their vascular specialist promptly — this magnitude of ABI drop indicates significant hemodynamic deterioration that warrants re-evaluation for PAD progression and possible revascularization planning. Similarly, new or worsening rest pain, new non-healing wounds, or sudden severe leg pain (which could indicate acute limb ischemia — a vascular emergency) always requires immediate medical evaluation rather than home monitoring adjustment.
The ABI in Diabetic Patients — Why Medial Arterial Calcification Matters
Diabetes mellitus creates a unique challenge for ABI interpretation because of medial arterial calcification (MAC) — a process distinct from intimal atherosclerosis in which calcium deposits form within the tunica media (middle layer) of the arterial wall, independent of luminal narrowing and lipid accumulation. MAC stiffens the arterial wall, making the artery incompressible by the external blood pressure cuff — resulting in falsely elevated ankle systolic pressures and consequently a falsely normal or elevated ABI (greater than 1.40) even in the presence of severe PAD:
The prevalence of MAC and consequent non-compressible arteries increases dramatically with diabetes duration and severity — affecting up to 30 to 40% of diabetic patients with neuropathy and up to 80% of diabetic patients undergoing lower extremity amputation. This is particularly dangerous because diabetic patients have the highest prevalence of PAD, the highest rate of progression to critical limb-threatening ischemia, and the most impaired wound healing capacity — yet the ABI may appear normal, falsely reassuring both patient and clinician. In any diabetic patient where MAC is suspected (ABI greater than 1.40, incompressible pedal arteries on examination, history of long-standing diabetes or renal insufficiency), the toe-brachial index (TBI) must be performed instead.
Digital arteries at the toes are rarely affected by MAC — the mechanism is unclear but likely related to the absence of medial smooth muscle in the terminal digital arterial walls. The TBI is therefore the preferred alternative to ABI in patients with non-compressible tibial arteries. A photoplethysmography (PPG) sensor or strain gauge plethysmography cuff is placed at the base of the great toe (or second or third toe if the great toe is absent or gangrenous), and a small blood pressure cuff inflated to occlude the digital artery. The TBI is calculated as the great toe systolic pressure divided by the brachial systolic pressure. Normal TBI is 0.70 or greater; TBI less than 0.70 defines PAD in patients with non-compressible tibial arteries. TBI less than 0.30 or absolute toe systolic pressure less than 30 mmHg indicates critical limb-threatening ischemia with very high risk of non-healing wounds and amputation — a threshold that should trigger urgent vascular surgery referral.
ABI as a Cardiovascular Risk Marker Beyond PAD
One of the most important aspects of the ABI test is its power to reclassify cardiovascular risk — identifying high-risk patients who would otherwise be categorized as intermediate risk by conventional Framingham-based risk scores and might not receive optimal preventive therapy:
The Ankle Brachial Index Collaboration’s meta-analysis of over 48,000 individuals across 16 cohort studies demonstrated that an ABI below 0.90 — compared to a reference ABI of 1.11 to 1.20 — approximately doubles the 10-year cardiovascular mortality risk in men (hazard ratio 2.2) and women (hazard ratio 2.4), independent of Framingham Risk Score. Adding ABI to Framingham Risk Score improved reclassification in men (net reclassification improvement of 19%) — particularly for men in the intermediate-risk category (10-year cardiovascular risk 10 to 20%) who would be reclassified upward to high risk, altering treatment thresholds for statin initiation, blood pressure targets, and antiplatelet therapy.
European Society of Cardiology guidelines incorporate ABI as a risk modifier: an ABI below 0.90 in a patient in the moderate or high-risk category automatically upgrades them to high-risk or very-high-risk, triggering LDL targets below 70 mg/dL and 55 mg/dL respectively. The ABI is therefore not just a test for leg symptoms — it is a tool for refining systemic cardiovascular risk stratification and optimizing preventive cardiovascular therapy in a way that standard risk calculators cannot provide.
Comparing the ABI to Other Peripheral Vascular Tests
The ABI is the starting point in the peripheral vascular diagnostic pathway. Understanding its role relative to other tests helps patients understand why additional investigation may be recommended after an abnormal ABI:
ABI versus segmental limb pressures and pulse volume recordings (PVRs): Segmental limb pressure measurement involves applying multiple blood pressure cuffs at the thigh, above-knee, below-knee, and ankle levels and measuring systolic pressure at each segment — allowing localization of the obstruction level (pressure drop of greater than 20 mmHg between two adjacent segments indicates obstruction between those levels). PVR recordings use a plethysmography cuff to measure the volume change in the limb with each cardiac pulse — a qualitative waveform that supplements the pressure measurements. Together, segmental pressures and PVRs provide hemodynamic localization of PAD that the simple ABI cannot provide — though they do not replace imaging for revascularization planning.
ABI versus lower extremity arterial duplex ultrasound: The ABI confirms PAD and quantifies severity but does not identify which specific artery is diseased, where the stenosis or occlusion is located, or the morphology of the lesion. Lower extremity arterial duplex ultrasound maps the anatomy and hemodynamics of PAD from the aortoiliac segment through the tibial vessels, identifying the specific stenosis or occlusion responsible for the ABI abnormality — information required for revascularization planning (balloon angioplasty versus stenting versus bypass surgery).
ABI versus CT angiography and invasive angiography: CTA and invasive angiography provide the highest-resolution three-dimensional anatomical imaging of the lower extremity arterial tree and are used for pre-operative planning when revascularization is intended. They are not appropriate for initial diagnosis or screening, for which the ABI remains the standard first-line tool because of its accessibility, low cost, and freedom from radiation and contrast risks.
The diagnostic pathway for PAD therefore typically runs: ABI (establish diagnosis and severity) → lower extremity arterial duplex (localize disease) → CTA or MRA (pre-operative planning) → invasive angiography (at the time of endovascular revascularization). The ABI is the essential gateway that initiates this pathway and determines its urgency.
Questions to Ask Your Doctor After an Abnormal ABI Result
When an ABI result comes back abnormal — below 0.90 confirming PAD — patients often feel uncertain about what questions to ask and what the diagnosis means for their daily life. Here are the most important questions to bring to your vascular specialist or cardiologist after an abnormal ABI:
What is my ABI number and what category does it fall in? Understanding whether your ABI indicates mild (0.71–0.90), moderate (0.41–0.70), or severe (below 0.40) PAD tells you how urgently intervention is needed and how aggressively symptoms should be monitored. A mild ABI may be managed with lifestyle modification and supervised exercise therapy alone; a moderate or severe ABI warrants imaging to plan potential revascularization.
Do I need a vascular ultrasound or other imaging? The ABI confirms PAD but does not identify which artery is blocked or where the obstruction is located. Imaging — typically lower extremity arterial duplex ultrasound — maps the anatomy and guides revascularization planning. Ask whether imaging is recommended based on your ABI severity and symptoms.
What cardiovascular risk does this ABI result carry? An ABI below 0.90 doubles cardiovascular event risk. Ask what this means for your specific situation: should your statin dose be increased? Should you start antiplatelet therapy? What blood pressure target applies to you? This framing shifts the ABI result from a leg diagnosis to a systemic cardiovascular care opportunity.
What exercise program is appropriate for my level of PAD? Supervised exercise therapy is the most effective treatment for claudication — but the appropriate exercise intensity and duration depends on your current walking tolerance and ABI severity. Ask for a referral to a structured vascular rehabilitation program if available in your area, or specific guidance on a home walking program if formal supervised exercise is not accessible.
How often should my ABI be re-tested? Patients with PAD typically undergo ABI surveillance every 12 months to monitor disease progression. A drop of 0.15 or greater from baseline ABI indicates significant hemodynamic deterioration requiring expedited re-evaluation. Understanding your monitoring schedule and the threshold for urgent re-evaluation prepares you to act promptly if your circulation deteriorates between scheduled appointments.